These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25236992)

  • 1. Mapping between the Roland Morris Questionnaire and generic preference-based measures.
    Khan KA; Madan J; Petrou S; Lamb SE
    Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
    Madan J; Khan KA; Petrou S; Lamb SE
    Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Selecting Covariates Using Factor Analysis in Mapping Algorithms Improve Predictive Accuracy? A Case of Predicting EQ-5D-5L and SF-6D Utilities from the Women's Health Questionnaire.
    Kaambwa B; Smith C; de Lacey S; Ratcliffe J
    Value Health; 2018 Oct; 21(10):1205-1217. PubMed ID: 30314622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping between headache specific and generic preference-based health-related quality of life measures.
    Khan K; Mistry H; Matharu M; Norman C; Petrou S; Stewart K; Underwood M; Achana F
    BMC Med Res Methodol; 2022 Oct; 22(1):277. PubMed ID: 36289468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain.
    Ye Z; Sun L; Wang Q
    Health Qual Life Outcomes; 2019 Apr; 17(1):57. PubMed ID: 30971265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
    Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
    Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.
    Obradovic M; Lal A; Liedgens H
    Health Qual Life Outcomes; 2013 Jul; 11():110. PubMed ID: 23815777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
    Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
    BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of EQ-5D and SF-6D utilities in mental health patients.
    Lamers LM; Bouwmans CA; van Straten A; Donker MC; Hakkaart L
    Health Econ; 2006 Nov; 15(11):1229-36. PubMed ID: 16625671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
    Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
    Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and Indirect Mapping of Assessment of Quality of Life - 6 Dimensions (AQoL-6D) Onto EQ-5D-5L Utilities Using Data From a Multicenter, Cross-Sectional Study of Malaysians With Chronic Heart Failure.
    Tan YJ; Ong SC
    Value Health; 2024 Dec; 27(12):1762-1770. PubMed ID: 39127252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
    Nikl A; Janssen MF; Jenei B; Brodszky V; Rencz F
    Pharmacoeconomics; 2024 May; 42(5):583-603. PubMed ID: 38416366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
    Dritsaki M; Petrou S; Williams M; Lamb SE
    Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.